Lower Gallilee, Israel

Ofer Reany


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Lower Gallilee, IL (2004 - 2005)
  • Lower Galilee, IL (2006)

Company Filing History:


Years Active: 2004-2006

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Ofer Reany: Innovator in Pharmaceutical Synthesis

Introduction

Ofer Reany is a notable inventor based in Lower Galilee, Israel, recognized for his contributions to the field of pharmaceutical synthesis. With a total of five patents to his name, Reany has made significant strides in the development of processes for synthesizing important pharmaceutical compounds.

Latest Patents

Reany's latest patents focus on the synthesis of racemic and optically active bicalutamide, a compound used in the treatment of prostate cancer. His innovative processes begin with ethyl pyruvate and methyl methacrylate, leading to the preparation of various bicalutamide intermediates. These include ethyl-[2-{4-fluorophenyl sulfone}]-2-hydroxy propionate, 1,2-epoxy-2-methyl propionate, and 2-hydrox-2-methyl-3-(4-fluorophenylthio) propionic acid. Additionally, he has developed methods for the isolation and purification of racemic and optically active bicalutamide, as well as micronized forms of the compound.

Career Highlights

Throughout his career, Ofer Reany has worked with prominent companies in the pharmaceutical industry, including Biogal Gyógyszergyár Rt. His work has contributed to advancements in drug synthesis and has had a positive impact on the pharmaceutical sector.

Collaborations

Reany has collaborated with notable professionals in his field, including Ben-Zion Dolitzky and Jenny Shammai. These partnerships have further enhanced his research and development efforts.

Conclusion

Ofer Reany's innovative work in the synthesis of pharmaceutical compounds showcases his expertise and dedication to advancing medical science. His contributions continue to influence the field and improve treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…